bomedemstat (MK-3543) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 4 Diseases   4 Trials   4 Trials   110 News 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bomedemstat (MK-3543) / Merck (MSD)
MK-3543-017, NCT06351631: A Study to Evaluate Safety and Efficacy of Bomedemstat

Recruiting
3
400
Europe, US, RoW
Bomedemstat, MK-3543, IMG-7289
Merck Sharp & Dohme LLC
Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera
12/34
12/34
MK-3543-007, NCT06456346: Bomedemstat vs Hydroxyurea for Essential Thrombocythemia

Recruiting
3
300
Europe, Japan, US, RoW
Bomedemstat, MK-3543, IMG-7289, Hydroxyurea, Bomedemstat placebo, Hydroxyurea placebo
Merck Sharp & Dohme LLC
Essential Thrombocythemia
04/27
04/29
MK-3543-006, NCT06079879: A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea

Recruiting
3
300
Europe, Canada, Japan, US, RoW
Bomedemstat, MK-3543, IMG-7289, Anagrelide, Busulfan, Interferon alfa/pegylated interferon alfa, Ruxolitinib
Merck Sharp & Dohme LLC
Essential Thrombocythemia
08/26
08/28
ChiCTR2400089201: A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadequate Response to or are Intolerant of Hydroxyurea.

Not yet recruiting
3
300
 
Bomedemstat; Best available treatment
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Merck Sharp & Dohme LLC
Essential thrombocythaemia
 
 
2021-002452-37: A study to test the safety and effects of Bomedemstat in patients with myeloproliferative neoplasm

Not yet recruiting
2
80
Europe
IMG-7289, IMG-7289, Capsule, hard
Imago BioSciences Inc., Imago BioSciences, Inc, Imago BioSciences, Inc.
Patients with Myeloproliferative Neoplasms (MPNs), MPN is a collective term for a number of blood cancers (diseases of the bone marrow) characterized by the overproduction of platelets. Patients have a high-risk of blood clots and bleeding., Diseases [C] - Cancer [C04]
 
 
2018-003811-23: A study to test the safety and effects of IMG-7289 in patients with myelofibrosis.

Not yet recruiting
2
75
Europe, RoW
IMG-7289, IMG-7289, Capsule, hard
Imago BioSciences, Inc., Imago BioSciences Inc., Imago BioSciences, Inc, Imago BioSciences, Inc.
Patients with myelofibrosis including primary myelofibrosis (PMF), post-polycythaemia vera myelofibrosis (PPV-MF), and post-essential thrombocythaemia myelofibrosis (PET-MF) (collectively referred to as ‘MF’), Myelofibrosis: a condition in which the bone marrow is gradually replaced by fibrous, scar-like tissue that prevents the marrow from making normal blood cells., Diseases [C] - Cancer [C04]
 
 
IMG-7289-CTP-201, NCT04254978 / 2019-003659-13: Study of Bomedemstat in Participants With Essential Thrombocythemia (/MK-3543-003)

Completed
2
73
Europe, US, RoW
Bomedemstat, IMG-7289, MK-3543
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Essential Thrombocythemia
03/23
03/23
NCT04081220: Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

Active, not recruiting
2
9
US
IMG-7289, LSD1 inhibitor
The University of Texas Health Science Center at San Antonio, Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Thrombocythemia, Essential
12/23
01/25
NCT04262141: IMG-7289 in Patients with Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

Active, not recruiting
2
4
US
IMG-7289, IMG7289, IMG 7289
Terrence J Bradley, MD, Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Essential Thrombocythemia, Polycythemia Vera
10/25
10/26
IMG-7289-CTP-202, NCT05223920: Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (/MK-3543-005)

Completed
2
81
Europe, US, RoW
Bomedemstat, IMG-7289, MK-3543
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Thrombocythemia, Essential, Primary Myelofibrosis
08/24
08/24
NCT05569538: Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis

Recruiting
2
40
RoW
Bomedemstat, IMG-7289
The University of Hong Kong, Imago BioSciences,Inc.
Myelofibrosis
12/24
12/25
MK-3543-004, NCT05558696: A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera

Active, not recruiting
2
20
Europe, US, RoW
Bomedemstat, MK-3543, IMG-7289
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Polycythemia Vera
03/25
03/25
NCT05191797: Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

Terminated
1/2
3
US
Bomedemstat, 1990504-34-1, IMG 7289, IMG-7289, LSD-1 Inhibitor IMG-7289, Lysine-specific Demethylase 1 Inhibitor IMG-7289, Atezolizumab, 1380723-44-3, Immunoglobulin G1, Anti-(human CD Antigen cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide with Human Monoclonal MPDL3280A Kappa-chain, Dimer, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq
University of Washington, National Cancer Institute (NCI), Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
08/23
04/24
ACTRN12621001349831: A phase I trial to study the effect of food on orally dosed IMG-7289 (Bomedemstat) in healthy adult volunteers

Completed
1
16
 
Avance Clinical, Imago BioSciences
Acute myeloid leukaemia (AML) , Myelodysplastic syndrome (MDS)
 
 
ACTRN12623001006639: An Open-Label, Phase 1 Study to Characterize the Effects of a Moderate CYP3A4 and P-glycoprotein Inhibitor on the Pharmacokinetics of Bomedemstat (IMG-7289) in Healthy Participants

Completed
1
20
 
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc.
Cancer
 
 
MK-3543-020, NCT06596668: Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants

Active, not recruiting
1
16
US
bomedemstat, MK-3543, carbamazepine
Merck Sharp & Dohme LLC
Healthy
02/25
03/25
VenBom, NCT05597306: Venetoclax and Bomedemstat in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Suspended
1
18
US
Bomedemstat, IMG-7289, Venetoclax, Venclexta
Terrence J Bradley, MD, Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
11/25
11/25

Download Options